Tevogen

Closed (deSPAC)

Profile in progress

What it is: Bio’s Next Generation Precision T Cell Platform Tevogen Bio’s next generation precision T cell platform is designed to provide increased immunologic specificity to eliminate malignant and virally infected cells, while allowing healthy cells to remain intact
What it’s doing now: Merging with Semper Paratus Acquisition Corp (LGST) — closed (despac).
What you should know: The deal carries a $25M minimum-cash condition — heavy redemptions can break it.

The business, per its filings

SEC primary

Bio’s Next Generation Precision T Cell Platform Tevogen Bio’s next generation precision T cell platform is designed to provide increased immunologic specificity to eliminate malignant and virally infected cells, while allowing healthy cells to remain intact. Multiple, precise candidate targets on viral or malignant cells are selected in advance for T cell sensitization and effector functions with the goal of overcoming the mutational escape capacity of cancer cells and viruses while limiting cross-reactivity. Tevogen Bio is investigating its technology’s potential to overcome the primary barriers to the broad application of personalized T cell therapies: potency, purity, production-at-scale, and patient-pairing, without the limitations of current approaches. Tevogen Bio’s goal is to provide access to the vast and unprecedented potential of developing personalized immunotherapies for large patient populations impacted by common cancers and viral infections. The ability to administer TVGN-489 in the outpatient setting and the ongoing work by Tevogen scientists to use this product in diverse patient populations, highlights Tevogen Bio’s commitment to patient accessibility. Advisors Cohen & Company Capital Markets, a division of J.V.B. Financial Group, LLC are serving as lead capital markets advisors to Semper Paratus. Nelson Mullins Riley & Scarborough LLP is serving as legal counsel to Semper Paratus, and Marcum LLP is serving as auditors to Semper Paratus. Hogan Lovells US LLP is serving as legal counsel to Tevogen Bio, and KPMG LLP is serving as auditors to Tevogen Bio.

What the company says about itself

Web research — not audited

What our web check found

[WEB-INTEL 2026-08-26] 8 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Tevogen Bio has raised funding over 3 rounds. Its first funding round was on Jan 25, 2021. Its latest funding round was a Grant (prize money) round on Jan 28, ..." [https://tracxn.com/d/companies/tevogen-bio/__CgGQW6mcoIR2TaZ_5nYJgZpdg-XIJUv9lmMKgdoVxEA] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Tevogen Bio has raised $50M in disclosed funding, most recently at Growth." [https://startupfundraising.com/founders/ryan-saadi] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Combination January 05, 2024 … is an expected $1.2 billion." [https://tevogen.com/press-release/tevogen-bio-inc-and-semper-paratus-acquisition-corporation-announce-effectiveness-of-registration-statement-for-business-combination/] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Semper Paratus (NASDAQ:LGST) has entered into a definitive agreement to combine with Tevogen Bio at an enterprise value of $1.2 billion." [https://www.spacinsider.com/news/deal-announcements-amendments/semper-paratus-lgst-to-combine-with-tevogen-bio-in-1-2bn-deal] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The Transaction, which has been approved by the boards of directors of Tevogen Bio and Semper Paratus, is expected to close near the end of 2023," [https://tevogen.com/press-release/semper-paratus-acquisition-corporation-files-registration-statement-on-form-s-4-in-connection-with-proposed-business-combination-with-tevogen-bio-inc/] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "TEVOGEN has raised a total of $120M of funding over 12 rounds. Their latest funding round was raised on May 12, 2026 in the amount of $14Mas a post_ipo_equity." [https://leadiq.com/c/tevogen/60602b4cf75c47a091bf6486] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Management believes that cash of $ 692,305 as of March 31, 2026, net proceeds of $ 0.1 million received from sales of common stock under the ..." [https://www.stocktitan.net/sec-filings/TVGN/10-q-tevogen-bio-holdings-inc-quarterly-earnings-report-272ecf07ea4e.html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Tevogen Reaffirms Oncology Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion." [https://tevogen.com/newsroom/]

Source: company web presence · marketing claims are reported as claims, never merged into the filed figures above.

The deal it’s entering

Tevogen is merging with Semper Paratus Acquisition Corp (LGST) currently marked Closed (deSPAC).

Headline equity value	—
Minimum cash to close	$25M

Structure per SEC accession(s) 0001493152-23-032665. How to read these numbers: headline vs effective valuation · what a definitive agreement commits

What exactly is being valued, and at what

Common questions

Is Tevogen going public?

Tevogen has an approved merger with the SPAC Semper Paratus Acquisition Corp (LGST). Deal status: Closed (deSPAC).

Does Tevogen have revenue?

The filings we've parsed don't state a usable revenue figure yet; this profile is updated as new documents land.

Educational content, not investment advice.